SCHEMBL7339097

SCHEMBL7339097

COc1ccc2ccc(C(=N)N)c(OC(=O)C(F)(F)F)c2c1Oc1ncccn1

nearest known ligand 0.35

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PLAU P00749 4/20 0.35
RAB9A P51151 4/20 0.33
NPC1 O15118 3/20 0.33
ALOX5AP P20292 1/20 0.33
FEN1 P39748 1/20 0.33
PKM P14618 1/20 0.33
ROCK2 O75116 3/20 0.32
NFE2L2 Q16236 1/20 0.31
F2 P00734 1/20 0.31
F3 P13726 1/20 0.31
LMNA P02545 1/20 0.31
MAPK1 P28482 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PRSS1 P07477 1/20 0.31
TMPRSS15 P98073 1/20 0.31
SYK P43405 1/20 0.31
MAPK8 P45983 1/20 0.31
MAPK10 P53779 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7337312 0.86 PLAU (0.39) PLAURAB9ANPC1LMNAMAPK1
SCHEMBL7339928 0.85 PLAU (0.35) PLAUF2F3LMNAMAPK1
SCHEMBL7342939 0.82 PLAU (0.34) PLAUF2PRSS1TMPRSS15SYK
SCHEMBL7335266 0.80 PLAU (0.35) PLAUF2
SCHEMBL7335828 0.79 MAPT (0.38) NPC1LMNAMAPK1SMN1; SMN2
SCHEMBL7337890 0.78 SMN1; SMN2 (0.39) PLAUNPC1PKMF2LMNA
SCHEMBL7351140 0.77 PLAU (0.51) PLAUROCK2F2PRSS1
SCHEMBL7344984 0.76 PLAU (0.49) PLAURAB9ANPC1ROCK2F2
SCHEMBL7337655 0.75 PLAU (0.50) PLAURAB9ANPC1PKMF2
Trifluoroacetic Acid SCHEMBL7339090 0.73 PLAU (0.57) PLAUF2F3PRSS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US claimed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP claimed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO claimed
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885RAB9A 2845/4885NPC1 2478/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.